Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
Clinical trial NCT04570631 · TERMINATED
Trial details
- NCT number
- NCT04570631
- Sponsor
- AbbVie
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-05
- Primary completion
- 2025-05-05
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.